Venlafaxine and GAD

NEW YORK, June 21 (Praxis Press) Generalized anxiety disorder (GAD) is associated with debilitating psychic and somatic symptoms. Previous studies have found that Venlafaxine extended-release (XR) capsules are effective in short-term treatment of patients with GAD, but without major depressive disorder (MDD). It is unclear, however, whether venlafaxine XR confers long-term benefits. Gelenberg and colleagues compared the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in 251 o

June 21, 2000

NEW YORK, June 21 (Praxis Press) Generalized anxiety disorder (GAD) is associated with debilitating psychic and somatic symptoms. Previous studies have found that Venlafaxine extended-release (XR) capsules are effective in short-term treatment of patients with GAD, but without major depressive disorder (MDD). It is unclear, however, whether venlafaxine XR confers long-term benefits. Gelenberg and colleagues compared the 6-month efficacy and safety of a flexible dosage of venlafaxine XR in 251 outpatients with GAD, without associated MDD, and compared them to controls taking a placebo (see article). During weeks 6 through 28 of the trial, response rates to standardized tests measuring anxiety in the venlafaxine XR group were 69% or higher compared with rates of 42% to 46% in the placebo group. The most common side effects were nausea, followed by somnolence and dry mouth. Venlafaxine XR is an effective, rapidly acting, safe, once-daily agent for both the short- and long-term treatment of anxiety.

Advertisement

Popular Now

  1. Mapping the Human Connectome
    Daily News Mapping the Human Connectome

    A new map of human cortex combines data from multiple imaging modalities and comprises 180 distinct regions.

  2. Will Organs-in-a-Dish Ever Replace Animal Models?
  3. Neurons Compete to Form Memories
  4. The Genetic Components of Rare Diseases
RayBiotech